CN112138053A - 一种用于治疗心脑血管疾病的药物组合物及其制备方法 - Google Patents

一种用于治疗心脑血管疾病的药物组合物及其制备方法 Download PDF

Info

Publication number
CN112138053A
CN112138053A CN202011225735.6A CN202011225735A CN112138053A CN 112138053 A CN112138053 A CN 112138053A CN 202011225735 A CN202011225735 A CN 202011225735A CN 112138053 A CN112138053 A CN 112138053A
Authority
CN
China
Prior art keywords
parts
dark plum
layer
pharmaceutical composition
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011225735.6A
Other languages
English (en)
Inventor
陆丽娜
康淑荷
王玉峰
孙初锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Minzu University
Original Assignee
Northwest Minzu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Minzu University filed Critical Northwest Minzu University
Priority to CN202011225735.6A priority Critical patent/CN112138053A/zh
Publication of CN112138053A publication Critical patent/CN112138053A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明公开了一种用于治疗心脑血管疾病的药物组合物及其制备方法，该组合物由以下重量份的原料构成：姬松茸10～20份、茯苓酸10～15份、银杏提取物10～20份、三七总皂苷10～15份、槲皮素5～10份、丹参总酚酸10～15份、刺芒柄花素5～10份、乌梅肉10～15份。本发明具有多成份、多环节、多靶点，且副作用小的特点，具有抗血小板聚集,抑制血栓血栓形成、抑制动脉粥样硬化的形成的功效。

Description

一种用于治疗心脑血管疾病的药物组合物及其制备方法
技术领域
本发明涉及中药制剂领域，具体涉及一种用于治疗心脑血管疾病的药物组合物及其制备方法。
背景技术
心脑血管疾病是心脏血管和脑血管疾病的统称，泛指由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病，主要诱发原因是动脉硬化造成管腔狭窄、管道阻塞，具有发病率高、死亡率高、致残率高、复发率高、并发症多、四高一多的特点。
目前，现有的心脑血管疾病治疗的西药普遍存在作用机理单一，副作用大，适用人群少的特点。
发明内容
为解决上述技术问题，本发明提供了一种用于治疗心脑血管疾病的药物组合物及其制备方法，具有多成份、多环节、多靶点，且副作用小的特点，具有抗血小板聚集,抑制血栓血栓形成、抑制动脉粥样硬化的形成的功效。
为实现上述目的，本发明采取的技术方案为：
一种用于治疗心脑血管疾病的药物组合物，该组合物由以下重量份的原料构成：
姬松茸10～20份、茯苓酸10～15份、银杏提取物10～20份、三七总皂苷10～15份、槲皮素5～10份、丹参总酚酸10～15份、刺芒柄花素5～10份、乌梅肉10～15份。
优选地，该组合物由以下重量份的原料构成：
姬松茸10份、茯苓酸10份、银杏提取物10份、三七总皂苷10份、槲皮素5份、丹参总酚酸10份、刺芒柄花素5份、乌梅肉10份。
优选地，该组合物由以下重量份的原料构成：
姬松茸20份、茯苓酸15份、银杏提取物20份、三七总皂苷15份、槲皮素10份、丹参总酚酸15份、刺芒柄花素10份、乌梅肉15份。
优选地，该组合物由以下重量份的原料构成：
姬松茸15份、茯苓酸12.5份、银杏提取物15份、三七总皂苷12.5份、槲皮素7.5份、丹参总酚酸12.5份、刺芒柄花素7.5份、乌梅肉12.5份。
本发明还提供了上述一种用于治疗心脑血管疾病的药物组合物的制备方法，包括如下步骤：
S1、将姬松茸粉碎至200目后，造粒，得粒径为25目～30目的微丸；
S2、将粉碎至200目，得乌梅粉，备用；
S3、以3%羟丙基甲基纤维素为黏合剂，开动机器，采用粉末层积法在微丸外部依次层积茯苓酸层、乌梅粉层、银杏提取物层、乌梅粉层、三七总皂苷层、乌梅粉层、槲皮素层、乌梅粉层、丹参总酚酸层、乌梅粉层、刺芒柄花素层、乌梅粉层，干燥，即得。
本发明还提供了上述一种用于治疗心脑血管疾病的药物组合物的质量控制方法，其基于茯苓酸、银杏提取物、三七总皂苷、槲皮素、丹参总酚酸、刺芒柄花素的纯度控制，其中，银杏提取物以银杏内酯、银杏总黄酮为标准。
本发明具有以下有益效果：
具有多成份、多环节、多靶点，且副作用小的特点，具有抗血小板聚集,抑制血栓血栓形成、抑制动脉粥样硬化的形成的功效。
具体实施方式
为了使本发明的目的及优点更加清楚明白，以下结合实施例对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
实施例1
一种用于治疗心脑血管疾病的药物组合物，通过以下方法制备所得：
S1、按重量份称取：姬松茸10份、茯苓酸10份、银杏提取物10份、三七总皂苷10份、槲皮素5份、丹参总酚酸10份、刺芒柄花素5份、乌梅肉10份；
S2、将姬松茸粉碎至200目后，造粒，得粒径为25目～30目的微丸；
S3、将粉碎至200目，得乌梅粉，备用；
S4、以3%羟丙基甲基纤维素为黏合剂，开动机器，采用粉末层积法在微丸外部依次层积茯苓酸层、乌梅粉层、银杏提取物层、乌梅粉层、三七总皂苷层、乌梅粉层、槲皮素层、乌梅粉层、丹参总酚酸层、乌梅粉层、刺芒柄花素层、乌梅粉层，干燥，即得。
实施例2
一种用于治疗心脑血管疾病的药物组合物，通过以下方法制备所得：
S1、按重量份称取：姬松茸20份、茯苓酸15份、银杏提取物20份、三七总皂苷15份、槲皮素10份、丹参总酚酸15份、刺芒柄花素10份、乌梅肉15份；
S2、将姬松茸粉碎至200目后，造粒，得粒径为25目～30目的微丸；
S3、将粉碎至200目，得乌梅粉，备用；
S4、以3%羟丙基甲基纤维素为黏合剂，开动机器，采用粉末层积法在微丸外部依次层积茯苓酸层、乌梅粉层、银杏提取物层、乌梅粉层、三七总皂苷层、乌梅粉层、槲皮素层、乌梅粉层、丹参总酚酸层、乌梅粉层、刺芒柄花素层、乌梅粉层，干燥，即得。
实施例3
一种用于治疗心脑血管疾病的药物组合物，通过以下方法制备所得：
S1、按重量份称取：姬松茸15份、茯苓酸12.5份、银杏提取物15份、三七总皂苷12.5份、槲皮素7.5份、丹参总酚酸12.5份、刺芒柄花素7.5份、乌梅肉12.5份；
S2、将姬松茸粉碎至200目后，造粒，得粒径为25目～30目的微丸；
S3、将粉碎至200目，得乌梅粉，备用；
S4、以3%羟丙基甲基纤维素为黏合剂，开动机器，采用粉末层积法在微丸外部依次层积茯苓酸层、乌梅粉层、银杏提取物层、乌梅粉层、三七总皂苷层、乌梅粉层、槲皮素层、乌梅粉层、丹参总酚酸层、乌梅粉层、刺芒柄花素层、乌梅粉层，干燥，即得。
经试验验证，本发明所得的组合物具有抗血小板聚集,抑制血栓血栓形成、抑制动脉粥样硬化的形成的功效。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以作出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (6)

1.一种用于治疗心脑血管疾病的药物组合物，其特征在于，该组合物由以下重量份的原料构成：
姬松茸10～20份、茯苓酸10～15份、银杏提取物10～20份、三七总皂苷10～15份、槲皮素5～10份、丹参总酚酸10～15份、刺芒柄花素5～10份、乌梅肉10～15份。
2.如权利要求1所述的一种用于治疗心脑血管疾病的药物组合物，其特征在于，该组合物由以下重量份的原料构成：
姬松茸10份、茯苓酸10份、银杏提取物10份、三七总皂苷10份、槲皮素5份、丹参总酚酸10份、刺芒柄花素5份、乌梅肉10份。
3.如权利要求1所述的一种用于治疗心脑血管疾病的药物组合物，其特征在于，该组合物由以下重量份的原料构成：
姬松茸20份、茯苓酸15份、银杏提取物20份、三七总皂苷15份、槲皮素10份、丹参总酚酸15份、刺芒柄花素10份、乌梅肉15份。
4.如权利要求1所述的一种用于治疗心脑血管疾病的药物组合物，其特征在于，该组合物由以下重量份的原料构成：
姬松茸15份、茯苓酸12.5份、银杏提取物15份、三七总皂苷12.5份、槲皮素7.5份、丹参总酚酸12.5份、刺芒柄花素7.5份、乌梅肉12.5份。
5.如权利要求1～4任一项所述的一种用于治疗心脑血管疾病的药物组合物的制备方法，其特征在于，包括如下步骤：
S1、将姬松茸粉碎至200目后，造粒，得粒径为25目～30目的微丸；
S2、将粉碎至200目，得乌梅粉，备用；
S3、以3%羟丙基甲基纤维素为黏合剂，开动机器，采用粉末层积法在微丸外部依次层积茯苓酸层、乌梅粉层、银杏提取物层、乌梅粉层、三七总皂苷层、乌梅粉层、槲皮素层、乌梅粉层、丹参总酚酸层、乌梅粉层、刺芒柄花素层、乌梅粉层，干燥，即得。
6.如权利要求1～4任一项所述的一种用于治疗心脑血管疾病的药物组合物的质量控制方法，其特征在于：基于茯苓酸、银杏提取物、三七总皂苷、槲皮素、丹参总酚酸、刺芒柄花素的纯度控制，其中，银杏提取物以银杏内酯、银杏总黄酮为标准。
CN202011225735.6A 2020-11-05 2020-11-05 一种用于治疗心脑血管疾病的药物组合物及其制备方法 Pending CN112138053A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011225735.6A CN112138053A (zh) 2020-11-05 2020-11-05 一种用于治疗心脑血管疾病的药物组合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011225735.6A CN112138053A (zh) 2020-11-05 2020-11-05 一种用于治疗心脑血管疾病的药物组合物及其制备方法

Publications (1)

Publication Number Publication Date
CN112138053A true CN112138053A (zh) 2020-12-29

Family

ID=73953978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011225735.6A Pending CN112138053A (zh) 2020-11-05 2020-11-05 一种用于治疗心脑血管疾病的药物组合物及其制备方法

Country Status (1)

Country Link
CN (1) CN112138053A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101073598A (zh) * 2006-05-17 2007-11-21 天津药物研究院 一种治疗心脑血管病的药物组合物及其制剂
CN101596185A (zh) * 2009-07-10 2009-12-09 西安交通大学 刺芒柄花素制备治疗高血压及缺血性心、脑血管疾病的药物用途
CN109045045A (zh) * 2018-08-14 2018-12-21 淮南师范学院 一种治疗心脑血管疾病的中药活性成分组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101073598A (zh) * 2006-05-17 2007-11-21 天津药物研究院 一种治疗心脑血管病的药物组合物及其制剂
CN101596185A (zh) * 2009-07-10 2009-12-09 西安交通大学 刺芒柄花素制备治疗高血压及缺血性心、脑血管疾病的药物用途
CN109045045A (zh) * 2018-08-14 2018-12-21 淮南师范学院 一种治疗心脑血管疾病的中药活性成分组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASK6037256437: "中药干乌梅能直接泡水喝吗有什么作用", 《HTTPS://TAG.120ASK.COM/JINGYAN/8LWM3LBTO0WMAOWVMH.HTML》 *
李思佳等: "银杏药理作用研究进展", 《药物评价研究》 *
李阳杰等: "具有抗癌活性的槲皮素衍生物研究进展", 《化学与黏合》 *
王振洲: "姬松茸特征简介", 《食药用菌》 *

Similar Documents

Publication Publication Date Title
He et al. Bletilla striata: Medicinal uses, phytochemistry and pharmacological activities
Zhang et al. Development of antioxidant chitosan film with banana peels extract and its application as coating in maintaining the storage quality of apple
Majewska et al. Proangiogenic activity of plant extracts in accelerating wound healing-a new face of old phytomedicines
More et al. The role of bioactive compounds on the promotion of neurite outgrowth
Jiang et al. The medicinal uses of the genus Bletilla in traditional Chinese medicine: A phytochemical and pharmacological review
Hosseini et al. Pulmonary fibrosis: Therapeutic and mechanistic insights into the role of phytochemicals
King et al. Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents
JP7511915B2 (ja) がん、炎症または免疫介在性炎症性疾患の防止および処置のためのカンナビノイドおよび医療用マッシュルームの固定した用量の組合せ
AU2005323436A1 (en) Bioactive compounds and methods of uses thereof
RU2007135252A (ru) Фармацевтическая композиция для лечения депрессии и способ ее получения
WO2004091645A2 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
YANG et al. Sanghuang industry in China: Current status, challenges and perspectives: The Qiandao Lake declaration for sanghuang industry development
Cheng-Yuan et al. Research progress on the prevention and treatment of hyperuricemia by medicinal and edible plants and its bioactive components
Huang et al. The traditional uses, secondary metabolites, and pharmacology of Eleutherococcus species
CN105362241A (zh) 一种精制人参片剂的制备方法
CN112138053A (zh) 一种用于治疗心脑血管疾病的药物组合物及其制备方法
Ikewuchi et al. Alteration of blood pressure indices and pulse rates by an aqueous extract of the leaves of Chromolaena odorata (L) King and Robinson (Asteraceae)
Sheena et al. Anti-inflammatory and anti-nociceptive activities of Ganoderma lucidum occurring in South India
CN1757399A (zh) 一种乌骨藤分散片及其制备方法
CN104491339A (zh) 一种防治高脂血症及抗血栓的沙棘叶组合物及制备方法
CN108578556A (zh) 一种降血糖降血脂的保健品及其制备方法
Kashani et al. Cytotoxic activity of selected Iranian traditional medicinal plants on colon, colorectal and breast cancer cell lines
CN103431380A (zh) 一种降低心肌耗氧及增加冠脉血流量的食疗产品
Sárpataki et al. Antiproliferative effect of Viscum album alcoholic extract in vitro.
CN103860818A (zh) 一种中药组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201229

RJ01 Rejection of invention patent application after publication